Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.170
Neutral
RSI(14)
43.484
Neutral
STOCH(KDJ)(9,3,3)
14.428
Oversold
ATR(14)
0.356
Low Volatility
CCI(14)
-169.809
Sell
Williams %R
81.818
Oversold
TRIX(12,20)
0.169
Sell
StochRSI(14)
29.840
Buy
Sophia Genetics SA
SOPH4.800USD
+0.200+4.35%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
325.67MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Sophia Genetics SA
Currency: USD Updated: 2026-02-06Key Insights
Sophia Genetics SA's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 152 out of 482 in the Software & IT Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 7.33.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sophia Genetics SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Sophia Genetics SA Highlights
StrengthsRisks
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 37.03% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 65.17M.
Undervalued
The company’s latest PE is -4.30, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.90M shares, decreasing 31.90% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 30.80K shares of this stock.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
7.333
Target Price
+46.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Sophia Genetics SA is 6.49, ranking 357 out of 482 in the Software & IT Services industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 19.46M, representing a year-over-year increase of 22.77%, while its net profit experienced a year-over-year increase of 8.59%.
Score
Financials
7.30
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.92
Operational Efficiency
5.42
Growth Potential
5.72
Shareholder Returns
7.07
Sophia Genetics SA's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Sophia Genetics SA is 7.12, ranking 322 out of 482 in the Software & IT Services industry. Its current P/E ratio is -4.30, which is -66.26% below the recent high of -1.45 and -19.94% above the recent low of -5.16.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 152/482
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Sophia Genetics SA is 9.00, ranking 6 out of 482 in the Software & IT Services industry. The average price target is 7.00, with a high of 9.00 and a low of 6.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
7.333
Target Price
+46.67%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
91
Total
4
Median
7
Average
Company name
Ratings
Analysts
Sophia Genetics SA
SOPH
4
Boston Scientific Corp
BSX
36
Intuitive Surgical Inc
ISRG
36
Edwards Lifesciences Corp
EW
35
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
18
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Sophia Genetics SA is 6.24, ranking 383 out of 482 in the Software & IT Services industry. Currently, the stock price is trading between the resistance level at 5.47 and the support level at 4.37, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
4.954
Sell
MA10
5.101
Sell
MA20
5.199
Sell
MA50
4.947
Sell
MA100
4.593
Buy
MA200
3.898
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Sophia Genetics SA is 3.00, ranking 280 out of 482 in the Software & IT Services industry. The latest institutional shareholding proportion is 39.65%, representing a quarter-over-quarter increase of 0.04%. The largest institutional shareholder is Al Gore, holding a total of 6.79M shares, representing 10.01% of shares outstanding, with 1.50% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Alychlo NV
aMoon Fund
Balderton Capital (UK) LLP
Camblong (Jurgi)
Banque Pictet & Cie S.A.
Alta Wealth Advisors LLC
Principal Global Investors (Equity)
Ossipow (Vincent)
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Software & IT Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sophia Genetics SA is 2.92, ranking 351 out of 482 in the Software & IT Services industry. The company's beta value is 1.13. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.13
VaR
--
240-Day Maximum Drawdown
+32.32%
240-Day Volatility
+87.43%
Return
Best Daily Return
60 days
+16.71%
120 days
+20.41%
5 years
--
Worst Daily Return
60 days
-8.00%
120 days
-9.26%
5 years
--
Sharpe Ratio
60 days
+0.92
120 days
+1.39
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+32.32%
3 years
+56.60%
5 years
--
Return-to-Drawdown Ratio
240 days
+0.69
3 years
+0.06
5 years
--
Skewness
240 days
+0.88
3 years
+0.41
5 years
--
Volatility
Realised Volatility
240 days
+87.43%
5 years
--
Standardised True Range
240 days
+5.89%
5 years
--
Downside Risk-Adjusted Return
120 days
+300.24%
240 days
+300.24%
Maximum Daily Upside Volatility
60 days
+54.49%
Maximum Daily Downside Volatility
60 days
+42.87%
Liquidity
Average Turnover Rate
60 days
+0.15%
120 days
+0.10%
5 years
--
Turnover Deviation
20 days
+50.91%
60 days
+55.85%
120 days
+2.65%
Peer Comparison
Software & IT Services
Sophia Genetics SA
SOPH
6.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
A10 Networks Inc
ATEN
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Visa Inc
V
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Progress Software Corp
PRGS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mastercard Inc
MA
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amdocs Ltd
DOX
8.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
